Tango Therapeutics, Inc. (TNGX)
The price, the headline numbers and the latest news, in one place.
Tango Therapeutics, Inc. (TNGX) Stock Price, Analysis & Data
| Bid | 21.55 |
| Market Cap | 4.01B |
| Revenue (ttm) | 53.8M |
| Net Income (ttm) | -124M |
| 1.12 | |
| -0.84 | |
| n/a | |
| -14.11 | |
| P/B (ttm) | 8.76 |
| P/S (ttm) | 74.51 |
| Earnings Date | Nov 4, 2026 |
| Ask | 36.82 |
| Volume | 2,279,285 |
| Avg. Volume (20D) | 3,070,283 |
| Open | 23.72 |
| Previous Close | 23.37 |
| Day's Range | 23.18 - 24.62 |
| 52-Week Range | 6.38 - 34.39 |
| Analyst | Strong<br>Buy |
| Price Target | 40 (68.21%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About TNGX
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. ...
Financial Performance
In 2025, Tango Therapeutics's revenue was 62.38M, an increase of 48.29% compared to the previous year's 42.07M. Earnings were -101.59M, a decrease of -22.03%.
Financial StatementsAnalyst Forecast
According to 11 analyst ratings, the average rating for TNGX stock is "Strong Buy". The 12-month stock price forecast is 40, which is upside of 68.21% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $0 misses estimates by $0, with -100.00% YoY decline.
- EPS of -0.37 misses estimates by -0.05, with -5.71% YoY decline.
Analysts project revenue of ... Upgrade
